Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript

Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Misses Revenue Estimates

Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019

Adamas Reports Third Quarter 2020 Financial Results

EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed a Memorandum of Understanding to settle one of the previously disclosed securities class-action lawsuits, Plymouth v. Adamas Pharmaceuticals, Inc., et al., Case No. RG19018715, pending in the California Superior Court for the County of Alameda.

Adamas announces settlement agreement of previously disclosed class action litigation

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

EMERYVILLE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Adrian Quartel, MD as Chief Medical Officer. As a member of the executive leadership team, Adrian will provide leadership and direction for all scientific and medical functions.

Adamas appoints new Chief Medical Officer, Adrian Quartel, MD

EMERYVILLE, Calif., Sept.  11, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress

EMERYVILLE, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific). 

Adamas to Present at Upcoming HC Wainwright Conference

EMERYVILLE, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen, and Baxter Healthcare as well as prior public-company Board, Audit, and Finance Committee experience at Cytyc Corporation.

Adamas Appoints Anna Richo to Board of Directors

Adamas Pharmaceuticals recently reported their Q2 earnings with a strong beat on EPS and revenue. The market responded appropriately with the stock nearly doubling in subsequent trading days.

Adamas Pharmaceuticals: Feeling Bullish After Impressive Growth In Q2

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q2 2020 Results - Earnings Call Transcript

Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

Adamas Reports Second Quarter 2020 Financial Results

Will Adamas Pharmaceuticals (ADMS) Report Negative Earnings Next Week? What You Should Know

EMERYVILLE, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

EMERYVILLE, Calif., July  15, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivotal trial data analysis at the American Academy of Neurology (AAN) Science Highlights Platform showing GOCOVRI decreasing dyskinesia and OFF time for people with Parkinson’s Disease (PD) using GOCOVRI® (amantadine) extended release capsules. GOCOVRI is indicated for the treatment of dyskinesia in people with Parkinson's disease receiving levodopa-based therapy. The  abstract  and  poster presentation  are available on the 2020 AAN Science Highlights Platform.

Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform

Adamas Pharmaceuticals (NASDAQ: ADMS) shares are trading lower on Thursday after the company reconfirmed it will not initiate further Phase 3 development in MSW.

Why Adamas Pharmaceuticals Is Trading Lower Today

EMERYVILLE, Calif., June  17, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of ADS-5102 in multiple sclerosis patients with walking impairment (MSW).

Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment

EMERYVILLE, Calif., June  04, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration (FDA). The anticipated Prescription Drug User Fee Act (PDUFA) action date is February 1, 2021. 

Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

EMERYVILLE, Calif., May  13, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI® (amantadine) extended release capsules. The new patent covers a method of reducing ‘OFF’ time and increasing ‘good ON’ time (ON time without troublesome dyskinesia) in people with Parkinson’s disease (PD) being treated with levodopa.  GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Data from two pivotal, placebo-controlled phase 3 clinical studies showed that GOCOVRI reduced dyskinesia, as well as a secondary benefit in reduction of OFF time, leading to an increase in good ON time.

Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time

Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q1 2020 Results - Earnings Call Transcript

First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019

Adamas Reports First Quarter 2020 Financial Results

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy

EMERYVILLE, Calif., April  10, 2020  (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees the option to purchase an aggregate of 86,000 shares of the company’s common stock, at a per share exercise price of $2.84, the closing trading price on April 7, and restricted stock units to acquire 43,000 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

News for Adamas Pharmaceuticals Stock (ADMS)